Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A Bayesian reanalysis of the effects of hydroxychloroquine and azithromycin on viral carriage in patients with COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genetic markers of abdominal obesity and weight loss after gastric bypass surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Maternal obesity and metabolic disorders associate with congenital heart defects in the offspring: A systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cancer in pregnancy increases the risk of venous thromboembolism: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Ovarian cancer is the leading cause of death among gynecologic malignancies. This is partly due to a non-durable response to chemotherapy. Prediction of resistance to chemotherapy could be a key role in more personalized treatment. In the current study we aimed to examine if microRNA based predictors could predict resistance to chemotherapy in ovarian cancer, and to investigate if the predictors could be prognostic factors for progression free and overall survival.

METHODS: Predictors of chemotherapy-resistance were developed based on correlation between miRNA expression and differences in measured growth inhibition in a variety of human cancer cell lines in the presence of Carboplatin, Paclitaxel and Docetaxel. These predictors were then, retrospectively, blindly validated in a cohort of 170 epithelial ovarian cancer patients treated with Carboplatin and Paclitaxel or Docetaxel as first line treatment.

RESULTS: In a multivariate cox proportional analysis the predictors of chemotherapy-resistance were not able to predict time to progression after end of chemotherapy (hazard ratio: 0.64, 95% CI: 0.36-1.12, P = 0.117). However, in a multivariate logistic analysis, where time to progression was considered as either more or less than 6 months, the predictors match clinical observed chemotherapy-resistance (odds ratio: 0.19, 95% CI: 0.05-0.73, P = 0.015). Neither univariate nor multivariate, time-dependent, cox analysis for progression free survival (PFS) or overall survival (OS) in all 170 patients showed to match predicted resistance to chemotherapy (PFS: hazard ratio: 0.69, 95% CI: 0.40-1.19, P = 0.183, OS: hazard ratio: 0.76, 95% CI: 0.42-1.40, P = 0.386).

CONCLUSION: In the current study, microRNA based predictors of chemotherapy-resistance did not demonstrate any convincing correlation to clinical observed chemotherapy-resistance, progression free survival, or overall survival, in patients with epithelial ovarian cancer. However the predictors did reflect relapse more or less than 6 months.

Original languageEnglish
JournalP L o S One
Volume12
Issue number3
Pages (from-to)e0174300
ISSN1932-6203
DOIs
Publication statusPublished - 23 Mar 2017

    Research areas

  • Journal Article

ID: 50607135